These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 29499835)
1. An update on β-lactamase inhibitor discovery and development. Docquier JD; Mangani S Drug Resist Updat; 2018 Jan; 36():13-29. PubMed ID: 29499835 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in the discovery of metallo-β-lactamase inhibitors for β-lactam antibiotic-resistant reversing agents. Guo Z; Ma S Curr Drug Targets; 2014; 15(7):689-702. PubMed ID: 24666360 [TBL] [Abstract][Full Text] [Related]
3. Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms. Koenig C; Kuti JL Pharmacotherapy; 2024 Aug; 44(8):658-674. PubMed ID: 38949413 [TBL] [Abstract][Full Text] [Related]
4. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Durand-Réville TF; Guler S; Comita-Prevoir J; Chen B; Bifulco N; Huynh H; Lahiri S; Shapiro AB; McLeod SM; Carter NM; Moussa SH; Velez-Vega C; Olivier NB; McLaughlin R; Gao N; Thresher J; Palmer T; Andrews B; Giacobbe RA; Newman JV; Ehmann DE; de Jonge B; O'Donnell J; Mueller JP; Tommasi RA; Miller AA Nat Microbiol; 2017 Jun; 2():17104. PubMed ID: 28665414 [TBL] [Abstract][Full Text] [Related]
5. Tackling the Antibiotic Resistance Caused by Class A Eiamphungporn W; Schaduangrat N; Malik AA; Nantasenamat C Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061509 [TBL] [Abstract][Full Text] [Related]
6. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Bush K Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989 [TBL] [Abstract][Full Text] [Related]
7. Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. Therrien C; Levesque RC FEMS Microbiol Rev; 2000 Jul; 24(3):251-62. PubMed ID: 10841972 [TBL] [Abstract][Full Text] [Related]
8. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276 [TBL] [Abstract][Full Text] [Related]
9. Game Changers: New β-Lactamase Inhibitor Combinations Targeting Antibiotic Resistance in Gram-Negative Bacteria. Bush K ACS Infect Dis; 2018 Feb; 4(2):84-87. PubMed ID: 29232103 [TBL] [Abstract][Full Text] [Related]
10. Novel non-β-lactam inhibitor of β-lactamase TEM-171 based on acylated phenoxyaniline. Grigorenko VG; Andreeva IP; Rubtsova MY; Deygen IM; Antipin RL; Majouga AG; Egorov AM; Beshnova DA; Kallio J; Hackenberg C; Lamzin VS Biochimie; 2017 Jan; 132():45-53. PubMed ID: 27771370 [TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Sharma R; Park TE; Moy S Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862 [TBL] [Abstract][Full Text] [Related]
12. Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria. Davies DT; Everett M Acc Chem Res; 2021 May; 54(9):2055-2064. PubMed ID: 33788541 [TBL] [Abstract][Full Text] [Related]
13. The Development of New Small-Molecule Inhibitors Targeting Bacterial Metallo-β-lactamases. Wang P; Cheng J; Liu CC; Tang K; Xu F; Yu Z; Yu B; Chang J Curr Top Med Chem; 2018; 18(10):834-843. PubMed ID: 29773066 [TBL] [Abstract][Full Text] [Related]
14. Stigmasterol: An adjuvant for beta lactam antibiotics against beta-lactamase positive clinical isolates. Yenn TW; Arslan Khan M; Amiera Syuhada N; Chean Ring L; Ibrahim D; Tan WN Steroids; 2017 Dec; 128():68-71. PubMed ID: 29104098 [TBL] [Abstract][Full Text] [Related]
15. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
16. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Nicolau DP Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447 [TBL] [Abstract][Full Text] [Related]